Prevtec Microbia has raised an undisclosed amount
Prevtec Microbia has raised an undisclosed amount.
Prevtec Microbia is a Canadian biotechnology company specialized in the development of vaccines and other technologies that help fight against bacterial diseases in animal foods, improve animal health and increase animal production performance. It is an innovation-centric company that operates in many areas through strategic alliances around the world.
Oaklins’ team in Montreal, Canada, advised Prevtec Microbia in the transaction.
Contacter l'équipe de la transaction
Transactions connexes
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
En apprendre plusLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
En apprendre plusEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
En apprendre plus